Skip to main content
SpringerLink
Log in

Nilotinib

  • Chapter
  • First Online:
Small Molecules in Hematology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 212))

Abstract

With imatinib still being linked to the breakthrough in CML therapy and probably being the most prescribed drug, second-generation TKIs are increasingly gaining importance. Showing higher response rates while not leading to more adverse events, nilotinib has become an attractive option in the first-line treatment of chronic-phase chronic myeloid leukemia. By reaching deep and long-lasting molecular remissions, discontinuation of TKIs is becoming one of the central topics of future CML therapy. Stopping nilotinib seems safe and provides a stable remission in about half of the eligible patients, though long-term data are still missing.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aichberger KJ, Herndlhofer S, Schernthaner G-H et al (2011) Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 86:533–539

    Article  CAS  PubMed  Google Scholar 

  • Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8:1018–1029

    Article  CAS  PubMed  Google Scholar 

  • Baccarani M, Cortes J, Pane F (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041–6051

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–894

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bradeen HA, Eide CA, O’Hare T et al (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108:2332–2338

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cortes JE, De Souza CA, Ayala M et al (2016) Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol 3:e581–e591

    Article  PubMed  Google Scholar 

  • Druker BJ, Tamura S, Buchdunger E, Ohno S (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566

    Article  CAS  PubMed  Google Scholar 

  • Druker BJ, Guilhot F, O’Brien S et al (2006) Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. J Clin Oncol 24:338S–338S

    Google Scholar 

  • Ernst T, La Rosee P, Mueller MC, Hochhaus A (2011) Bcr-Abl mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am 25:997–1008

    Article  PubMed  Google Scholar 

  • Giles FJ, Larson RA, Kantarjian HM (2008) Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib—Giles et al. 26 (15 supplement): 7017—ASCO meeting abstracts. J Clin Oncol 26:7017

    Google Scholar 

  • Giles FJ, Abruzzese E, Rosti G et al (2010) Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 24:1299–1301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Giles FJ, Kantarjian HM, le Coutre PD et al (2012) Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26:959–962

    Article  CAS  PubMed  Google Scholar 

  • Giles FJ, le Coutre PD, Pinilla-Ibarz J et al (2013) Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27:107–112

    Article  CAS  PubMed  Google Scholar 

  • Giles FJ, Rea D, Rosti G et al (2017) Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. J Cancer Res Clin Oncol 143:1585–1596

    Google Scholar 

  • Golemovic M, Verstovsek S, Giles F et al (2005) AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 11:4941–4947

    Article  CAS  PubMed  Google Scholar 

  • Gorre ME, Mohammed M, Ellwood K et al (2001) Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification. Science 293:876–880

    Article  CAS  PubMed  Google Scholar 

  • Haouala A, Widmer N, Duchosal MA et al (2011) Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 117:E75–E87

    Article  CAS  PubMed  Google Scholar 

  • Hochhaus A, Saglio G, Larson RA et al (2013) Nilotinib is associated with a reduced incidence of Bcr-Abl mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 121:3703–3708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hochhaus A, Saglio G, Hughes TP et al (2016a) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044–1054

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hochhaus A, Rosti G, Cross NCP et al (2016b) Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia 30:57–64

    Article  CAS  PubMed  Google Scholar 

  • Hochhaus A, Masszi T, Giles FJ et al (2017) Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia 31:1525–1531

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hughes P, Hochhaus A, Kantarjian H et al (2014a) Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Hematologica 99(7):1204–1211

    Article  CAS  Google Scholar 

  • Hughes TP, Saglio G, Kantarjian H et al (2014b) Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123:1353–1360

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hughes TP, Boquimpani C, Takahashi N et al (2016) Results from ENESTop: Treatment-free remission (TFR) following switch to nilotinib in patients with chronic myeloid leukemia in chronic phase. ASCO 2016 abstract #7054

    Google Scholar 

  • Jain P, Kantarjian H, Nazha A et al (2013) Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities. Blood 121:4867–4874

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kagan M, Tran P, Fischer V et al (2005) Safety, pharmacokinetics (PK), metabolism, and mass balance of [C-14]-AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects. Blood 106:302B–302B

    Google Scholar 

  • Kantarjian H, Giles F, Wunderle L et al (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542–2551

    Article  PubMed  Google Scholar 

  • Kantarjian HM, Giles F, Gattermann N et al (2007) Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540–3546

    Article  CAS  PubMed  Google Scholar 

  • Kantarjian HM, Giles FJ, Bhalla KN et al (2011a) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117:1141–1145

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kantarjian HM, Hochhaus A, Saglio G et al (2011b) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12:841–851

    Article  CAS  PubMed  Google Scholar 

  • Kim TD, Schwarz M, Nogai H et al (2010) Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid 20(11):1209–1214

    Article  CAS  PubMed  Google Scholar 

  • Kim TD, Rea D, Schwarz M et al (2013) Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 27:1316–1321

    Article  CAS  PubMed  Google Scholar 

  • Larson RA, Hochhaus A, Hughes TP et al (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26:2197–2203

    Article  CAS  PubMed  Google Scholar 

  • Larson RA, Hochhaus A, Saglio G et al (2013) Nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year update. J Clin Oncol (suppl) 31:abstr. 7052

    Google Scholar 

  • le Coutre P, Ottmann OG, Giles F et al (2008) Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:1834–1839

    Article  CAS  PubMed  Google Scholar 

  • le Coutre P, Rea D, Abruzzese E et al (2011) Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 103:1347–1348

    Article  CAS  PubMed  Google Scholar 

  • le Coutre PD, Giles FJ, Hochhaus A et al (2012) Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 26:1189–1194

    Article  CAS  PubMed  Google Scholar 

  • Mahon F-X, Rea D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 11:1029–1035

    Article  CAS  PubMed  Google Scholar 

  • Mahon FX, Richter J, Guilhot J et al (2016) Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the euro-ski trial. Blood 128:787

    Google Scholar 

  • Manley PW, Breitenstein W, Brüggen J et al (2004) Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDCFR kinases. Bioorg Med Chem Lett 14:5793–5797

    Article  CAS  PubMed  Google Scholar 

  • Mori S, Vagge E, le Coutre P et al (2015) Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol 90(10):910–914

    Article  CAS  PubMed  Google Scholar 

  • Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 142:1497

    Google Scholar 

  • O’Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500–4505

    Article  PubMed  Google Scholar 

  • O’Hare T, Eide CA, Deininger MWN (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:2242–2249

    Article  CAS  PubMed  Google Scholar 

  • Quintás-Cardama A, Kantarjian H, Cortes J (2012) Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 12:337–340

    Article  CAS  PubMed  Google Scholar 

  • Radich JP, Deininger M, Abboud CN et al (2017) NCCN guidelines version 1.2018 chronic myeloid leuemia. NCCN, Professionals, Physician Guidelines, Chronic Myeloid Leukemia. Accessed on Sept 10 2017

    Google Scholar 

  • Ray A, Cowan-Jacob SW, Manley PW et al (2007) Identification of Bcr-Abl point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 109:5011–5015

    Article  CAS  PubMed  Google Scholar 

  • Rea D, Rosti G, Cross N et al (2015) Enestpath: a phase III study to assess the effect of nilotinib treatment duration on treatment-free remission (TFR) in chronic phase-chronic myeloid leukemia (CP-CML) patients (pts) previously treated with imatinib: interim analysis from the first year of induction phase. Blood 126:4040

    Google Scholar 

  • Rea D, Nicolini FE, Tulliez M et al (2016) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 129:846–854

    Article  CAS  PubMed  Google Scholar 

  • Redaelli S, Mologni L, Rostagno R et al (2012) Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 87:E125–E128

    Article  CAS  PubMed  Google Scholar 

  • Rix U, Hantschel O, Duernberger G et al (2007) Chemical proteomic profiles of the Bcr-Abl inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets. Blood 110:4055–4063

    Article  CAS  PubMed  Google Scholar 

  • Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405):290–293

    Article  CAS  PubMed  Google Scholar 

  • Saglio G, Kim D-W, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251–2259

    Article  CAS  PubMed  Google Scholar 

  • Shah NP, Nicoll JM, Nagar B et al (2002) Multiple Bcr-Abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117–125

    Article  CAS  PubMed  Google Scholar 

  • Soverini S, Colarossi S, Gnani A et al (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res 12(24):7374–7379

    Article  CAS  PubMed  Google Scholar 

  • Steegmann JL, Baccarani M, Breccia M et al (2016) European leukemia net recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30:1648–1671

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tanaka C, Yin OQP, Sethuraman V et al (2009) Clinical pharmacokinetics of the Bcr-Abl tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87:197–203

    Article  CAS  PubMed  Google Scholar 

  • Tanaka C, Yin OQP, Smith T et al (2011) Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 51:75–83

    Article  CAS  PubMed  Google Scholar 

  • von Bubnoff N, Manley PW, Mestan J et al (2006) Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108:1328–1333

    Article  CAS  Google Scholar 

  • Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129–141

    Article  CAS  PubMed  Google Scholar 

  • Weisberg E, Manley P, Mestan J et al (2006) AMN107 (nilotinib): a novel and selective inhibitor of Bcr-Abl. Br J Cancer 94:1765–1769

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yin OQP, Gallagher N, Li A et al (2010) Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 50:188–194

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Medical Department, Charité Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117, Berlin, Germany

    Martin Gresse, Theo D. Kim & Philipp le Coutre

Authors
  1. Martin Gresse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theo D. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philipp le Coutre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Gresse .

Editor information

Editors and Affiliations

  1. MOLIT Institute, Cancer Center Heilbronn-Franken, SLK-Clinics, Heilbronn, Baden-Württemberg, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gresse, M., Kim, T.D., le Coutre, P. (2018). Nilotinib. In: Martens, U. (eds) Small Molecules in Hematology. Recent Results in Cancer Research, vol 212. Springer, Cham. https://doi.org/10.1007/978-3-319-91439-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-91439-8_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-91438-1

  • Online ISBN: 978-3-319-91439-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation